Liver transplant patients may finally get a break from lifelong drugs
NCT ID NCT07206277
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 29 times
Summary
This study tests whether a special ultrasound called fibroscan can help doctors safely lower the dose of anti-rejection drugs in liver transplant patients. These drugs are needed for life but can cause serious side effects like kidney damage, diabetes, and heart disease. The study will include 50 adults who are at least 2 years post-transplant and have no recent rejection or autoimmune liver disease. The goal is to reduce their medication by 30% without causing rejection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G2R3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.